Dose-dependent pharmacodynamic interaction between fasudil, a Rho kinase inhibitor, and doxorubicin in the MCF-7 breast cancer cell line

Authors

• Ahmed B. Abdulwahid, Lecturer, Department of Physiology, Al- Zahraa College of Medicine, University of Basrah, Basrah, Iraq
• Shaymaa F. Abbas, Lecturer, Department of Pharmacology, Al-Zahraa College of Medicine, University of Basrah, Basrah, IraqFollow
• Dhuha E. Omran, assistant lecturer, Department of Pharmacology, Al-Zahraa College of Medicine, University of Basrah, Basrah, Iraq
• Nehaya M. Al-Aubody, Professor. Department of Physiology, Al- Zahraa College of Medicine, University of Basrah, Basrah, Iraq
• Sara A. Yaseen, Al- Zahraa College of Medicine, University of Basrah, Basrah, Iraq

Abstract

Background: It is necessary to seek combination therapy that uses non-traditional cytotoxic drugs to mitigate the side effects of doxorubicin. Recently, Rho-associated protein kinase (ROCK) inhibitors have exhibited promising antitumor activity in both experimental and clinical studies

Aim: This study aimed to characterize the pharmacodynamic interaction between fasudil, a ROCK inhibitor, and doxorubicin in MCF-7 breast cancer cells by evaluating their cytotoxic effects and quantifying drug interactions using the Chou–Talalay principle.

Methods: Doxorubicin, fasudil, and their combined fractions were evaluated to investigate their cytotoxic impact on the MCF-7 cell line using the MTT  method. The cells were treated with six concentrations for 24 hours. Drug interactions were quantitatively evaluated using the Chou–Talalay principle to compute the combination index (CI) and the dose reduction index (DRI) with CompuSyn software.

Results: Both doxorubicin and fasudil showed concentration-dependent cytotoxic activity, but doxorubicin showed greater potency. When used in combination, they exhibited mild antagonism at IC₅₀ (CI > 1 and DRI < 1), which shifted to synergism at IC90 and IC95 (CI < 1 and DRI > 1).

Conclusion: Fasudil showed limited cytotoxicity alone but demonstrated an effect-level-dependent interaction with doxorubicin, shifting from slight antagonism at IC₅₀ to model-predicted synergism at higher effect levels. Our findings encourage further investigation of fasudil as an adjuvant to doxorubicin therapy.

Recommended Citation

Abdulwahid, Ahmed B.; Abbas, Shaymaa F.; Omran, Dhuha E.; Al-Aubody, Nehaya M.; and Yaseen, Sara A. (2026) "Dose-dependent pharmacodynamic interaction between fasudil, a Rho kinase inhibitor, and doxorubicin in the MCF-7 breast cancer cell line," Maaen Journal for Medical Sciences: Vol. 5 : Iss. 4 , Article 1.
Available at: https://doi.org/10.55810/2789-9136.1110

References

[1] Bisht A, Avinash D, Sahu KK, Patel P, Das Gupta G, Kurmi BD. A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Deliv Transl Res 2025;15(1):102—33.

[2] Nunes KP, Webb RC. New insights into RhoA/Rho-kinase signaling: a key regulator of vascular contraction. Small GTPases 2021;12(5—6):458—69.

[3] Guan G, Cannon RD, Coates DE, Mei L. Effect of the RhoKinase/ROCK signaling pathway on cytoskeleton components. Genes 2023;14(2):272.

[4] Liu L-C, Chen Y-H, Lu D-W. The application of rho kinase inhibitors in the management of glaucoma. Int J Mol Sci 2024;25(11):5576.

[5] Abedi F, Omidkhoda N, Arasteh O, Ghavami V, Hosseinzadeh H. The therapeutic role of rho kinase inhibitor, fasudil, on pulmonary hypertension; a systematic review and meta-analysis. Drug Research 2023;73(1):5—16.

[6] Lai A, Frishman WH. Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol Rev 2005;13(6):285—92.

[7] Riches DW, Backos DS, Redente EF. ROCK and Rho: promising therapeutic targets to ameliorate pulmonary fibrosis. Am J Pathol 2015;185(4):909—12.

[8] Li J, Zhang B, Lu P, Li B. Effect of Fasudil on neuronal apoptosis and expression of BCL-2 protein after acute spinal cord injury in rats. Chin J Neurotraumatic Surg 2024;10(2):65 (Electronic Edition).

[9] Morgan-Fisher M, Wewer UM, Yoneda A. Regulation of ROCK activity in cancer. J Histochem Cytochem 2013;61(3): 185—98.

[10] Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 2008;33(3): 585—93.

[11] Wu Q, Ma X, Jin Z, Ni R, Pan Y, Yang G. Zhuidu Formula suppresses the migratory and invasive properties of triplenegative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK. J Ethnopharmacol 2023; 315:116644.

[12] Wu Q, Leng X, Ma X, Xu Q, Ni R, Pan Y, et al. Triptolide Reduces MDA-MB-231 cell metastasis by attenuating epithelial-mesenchymal transition through the ROCK/ PTEN/Akt Axis. Chem Biodivers 2023;20(12):e202300399.

[13] Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009;69(22): 8742—51.

[14] Deng L, Li G, Li R, Liu Q, He Q, Zhang J. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol Ther 2010;9(11):875—84.

[15] Huang Y, Wang S, Zhang X, Yang C, Wang S, Cheng H, et al. Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway. Pharmacol Res 2024;200:107082.

[16] Wu Y, Jiang Y, Jiang L, Peng Y, Zhou T, Xia X, et al. Phospho-cofilin predicts efficiency of Fasudil for oral squamous cell carcinoma treatment through Yes-associated protein inhibition. Arch Oral Biol 2025;172:106185.

[17] Barcelo J, Samain R, Sanz-Moreno V. Preclinical to clinical utility of ROCK inhibitors in cancer. Trends Cancer 2023; 9(3):250—63.

[18] Guerra FS, Oliveira RGd, Fraga CAM, Mermelstein CdS, Fernandes PD. ROCK inhibition with Fasudil induces betacatenin nuclear translocation and inhibits cell migration of MDA-MB 231 human breast cancer cells. Sci Rep 2017;7(1): 13723.

[19] Gogebakan B, Bayraktar R, Suner A, Balakan O, Ulasli M, Izmirli M, et al. Do Fasudil and Y-27632 affect the level of transient receptor potential (TRP) gene expressions in breast cancer cell lines? Tumor Biol 2014;35(8):8033—41

[20] Liang J, Tang M, Wang L. The novel ROCK inhibitor fasudil derivative fasudil-D-6h prevents tumour progression by regulating the adherens junction signalling pathway in triple-negative breast cancer. Breast Cancer 2026:547003.

[21] Abbas SF, Al-Hashemi HA, Omran DE, Baqir QK. Exploring cytotoxic and apoptotic effects of rosuvastatin on lung cancer cell line. J Contemp Med Sci 2025;11(1):50—4.

[22] Abbas SF, Abdulwahid AB, Omran DE, Al-Aubody NM, Albadran MF. Does valsartan affect the cytotoxicity of doxorubicin when used as a cardioprotective drug against doxorubicin-induced cardiotoxicity? Iraqi Natl J Lab Med 2026;8(1):44—9.

[23] Ying H, Biroc SL, Li W-w, Alicke B, Xuan J-A, Pagila R, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Therapeut 2006;5(9):2158—64.

[24] Wang Y, Zhang Y, Zhang D. Rho/Rho kinase signaling pathway and disease: from bed to bench. Front Cardiovasc Drug Discov 2022;6:54—101.

[25] Cheng Z, Erhardt S, Wang J. Rho/ROCK pathway as a therapeutic target in multiple diseases. Int J Drug Discov Pharmacol 2025;4(3). https://doi.org/10.53941/ ijddp.2025.100018.

[26] Crosas-Molist E, Samain R, Kohlhammer L, Orgaz JL, George SL, Maiques O, et al. Rho GTPase signaling in cancer progression and dissemination. Physiol Rev 2022; 102(1):455—510.

[27] Zhang X, Wu N. Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells. Drug Des Dev Ther 2018;12(null):373—81.

[28] Liao T, Deng J, Chen W, Xu J, Yang G, Zhou M, et al. fasudil increased the sensitivity to gefitinib in NSCLC by decreasing intracellular lipid accumulation. Cancers 2022; 14(19):4709.

[29] Kan L, Smith A, Chen M, Ledford BT, Fan H, Liu Z, et al. Rho-associated kinase inhibitor (Y-27632) attenuates doxorubicin-induced apoptosis of human cardiac stem cells. PLoS One 2015;10(12):e0144513.

[30] Shahbazi R, Baradaran B, Khordadmehr M, Safaei S, Baghbanzadeh A, Jigari F, et al. Targeting ROCK signaling in health, malignant and non-malignant diseases. Immunol Lett 2020;219:15—26.

[31] Huo Z, Su Y, Dong Y, Zheng Y, Zhang Q, Duan Y, et al. Rhokinase inhibition by Fasudil promotes tumor maturation and apoptosis in small-cell lung cancer. Am J Transl Res 2020;12(8):4354.

[32] Zhang X, Liu X, Zhou W, Yang M, Ding Y, Wang Q, et al. Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. Cell Death Dis 2018;9(2):190.